Literature DB >> 16884382

Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma.

W Wu1, B M Slomovitz, P T Soliman, K M Schmeler, J Celestino, M R Milam, K H Lu.   

Abstract

Cyclins D1 and D3 play key roles in cell cycle progression. The downregulation of cyclin D3 was associated with phosphatase and tensin homolog deleted on chromosome ten-(PTEN)-induced cell cycle arrest. We attempted to determine whether cyclin D1 and D3 overexpression is correlated with PTEN inactivation in endometrioid endometrial cancer (EEC). The expression of PTEN, cyclin D1, and cyclin D3 were determined by immunohistochemical analysis in 105 EEC specimens. Forty-three percent of the EEC demonstrated loss of PTEN expression. Cyclin D3 was overexpressed in only 18% of the EEC specimens and was not associated with tumor grade. Cyclin D1 was overexpressed in 64% of the specimens and was more common in moderate or high-grade tumors (P = 0.002 and P = 0.02, respectively). The overexpression of cyclin D3 was not correlated with loss of PTEN in the EEC. The overexpression of cyclin D1 was much higher in grade 1 tumors with negative PTEN than tumors with positive PTEN expression (67% vs 26%). The overexpression of cyclin D3 was neither frequent nor correlated with the loss of PTEN expression. The overexpression of cyclin D1 was higher in the low-grade tumors with negative PTEN expression than tumors with positive PTEN expression. Overexpression of cyclin D1 is frequent in moderate or high-grade EECs and likely results from multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884382     DOI: 10.1111/j.1525-1438.2006.00642.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 2.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

Review 3.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

4.  Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor.

Authors:  Hongliang Zong; Yayun Chi; Yanlin Wang; Yanzhong Yang; Li Zhang; Haijiao Chen; Jianhai Jiang; Zejuan Li; Yi Hong; Hanzhou Wang; Xiaojing Yun; Jianxin Gu
Journal:  Mol Cell Biol       Date:  2007-08-13       Impact factor: 4.272

5.  miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.

Authors:  Bairong Xia; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Mol Cancer       Date:  2015-03-11       Impact factor: 27.401

6.  Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway.

Authors:  Juan Qiao; Wei-Jing Wang; Yuan Zhang
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

Review 7.  Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.

Authors:  Bo Wang; Zijian Wang; Lizhi Han; Song Gong; Yanxue Wang; Zhiwen He; Yong Feng; Zhaohui Yang
Journal:  Cancer Cell Int       Date:  2019-06-10       Impact factor: 5.722

8.  Expression of Cyclin D1 in Hyperplasia and Carcinoma of Endometrium and Its Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features.

Authors:  Karuna Sangwan; Monika Garg; Nayana Pathak; Lavleen Bharti
Journal:  J Lab Physicians       Date:  2020-11-23

9.  Cross-talk between p21-activated kinase 4 and ERα signaling triggers endometrial cancer cell proliferation.

Authors:  Tao Su; Jun-Jie Qu; Kai Wang; Bi-Lan Li; Dong Zhao; Yi-Ping Zhu; Lei Ye; Wen Lu; Xiao-Ping Wan
Journal:  Oncotarget       Date:  2017-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.